Drugs / BR4002-1
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT04462029 | Jun → Oct 2020 | Alzheimer disease | Boryung Pharmaceutical Co., Ltd | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BR4002-1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04462029 ↗ |
| Route | Oral | “BR4002-1 (oral formulation) will be administered with 150 mL of water” NCT04462029 ↗ |